KatsikiNMikhailidisDPMantzorosCS. Non-alcoholic fatty liver disease and dyslipidemia: An update. Metabolism. 2016; 65: 1109–23.
2.
BisacciaGRicciFMantiniC, et al.Nonalcoholic fatty liver disease and cardiovascular disease phenotypes. SAGE Open Med. 2020;8:2050312120933804.
3.
DoumasMImprialosKStavropoulosKAthyrosVG. What Does the Future Hold for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis?Curr Vasc Pharmacol. 2019;17:425–8.
4.
YaylaÇYaylaKGKaranfilM, et al.The Nonalcoholic Fatty Liver Disease and Cardiovascular Diseases. Angiology. 2020; 71: 87.
5.
AthyrosVGAlexandridesTKBilianouH, et al.The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non- alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. Metabolism. 2017; 71: 17–32.
AthyrosVGTziomalosKGossiosTD, et al.Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet. 2010; 376: 1916–22.
8.
TikkanenMJFayyadRFaergemanO, et al.Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels. Int J Cardiol. 2013; 168: 3846–52.
9.
Al BatranRGopalKAburasaynH, et al.The antianginal ranolazine mitigates obesity-induced nonalcoholic fatty liver disease and increases hepatic pyruvate dehydrogenase activity. JCI Insight. 2019; 4:e124643.
10.
EsenbogaKKurtulANazmanH, et al.Evaluation of the impact of ranolazine treatment on liver function tests in patients with coronary heart disease and non-alcoholic fatty liver disease. Angiology. 2021; (in press).
11.
Mahjoubin-TehranMDe VincentisAMikhailidisDP, et al.Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis. Mol Metab. 2020 Jul13:101049. doi:10.1016/j.molmet.2020.101049 Epub ahead of print. PMID: 32673798.
12.
ZhangYLiCLiX, et al.Trimetazidine improves hepatic lipogenesis and steatosis in nonalcoholic fatty liver disease via AMPK-ChREBP pathway. Mol Med Rep. 2020;22:2174–82.
13.
LiRTangXJingQ, et al.The effect of trimetazidine treatment in patients with type 2 diabetes undergoing percutaneous coronary intervention for AMI. Am J Emerg Med. 2017;35:1657–61.
